CNTA RSI Chart
Last 7 days
6.9%
Last 30 days
-15.7%
Last 90 days
21.3%
Trailing 12 Months
120.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 0 | 0 | 0 | 6.9M |
2022 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 31, 2024 | hussain iqbal j | sold (taxes) | -84,976 | 11.3 | -7,520 | general counsel |
Mar 31, 2024 | chao david m | sold (taxes) | -117,350 | 11.3 | -10,385 | chief administrative officer |
Mar 31, 2024 | weinhoff gregory m | sold (taxes) | -132,685 | 11.3 | -11,742 | chief financial officer |
Mar 31, 2024 | saha saurabh | sold (taxes) | -409,772 | 11.3 | -36,263 | chief executive officer |
Mar 31, 2024 | bush tia l | sold (taxes) | -72,534 | 11.3 | -6,419 | chief technology & quality ofc |
Mar 25, 2024 | anderson karen m. | sold | -607,960 | 11.8835 | -51,160 | chief people officer |
Mar 25, 2024 | anderson karen m. | acquired | 177,252 | 3.93892 | 45,000 | chief people officer |
Feb 01, 2024 | bush tia l | sold (taxes) | -31,629 | 8.19 | -3,862 | chief quality officer |
Feb 01, 2024 | hussain iqbal j | acquired | - | - | 42,500 | general counsel |
Feb 01, 2024 | anderson karen m. | acquired | - | - | 31,250 | chief people officer |
Which funds bought or sold CNTA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
May 01, 2024 | Compagnie Lombard Odier SCmA | sold off | -100 | -46,327 | - | -% |
May 01, 2024 | Tanager Wealth Management LLP | unchanged | - | 2,324,960 | 7,865,880 | 1.27% |
Apr 29, 2024 | China Universal Asset Management Co., Ltd. | added | 69.17 | 71,000 | 122,000 | 0.02% |
Apr 25, 2024 | Zurcher Kantonalbank (Zurich Cantonalbank) | new | - | 25,617 | 25,617 | -% |
Apr 24, 2024 | Spire Wealth Management | unchanged | - | 224 | 791 | -% |
Apr 23, 2024 | Global Retirement Partners, LLC | unchanged | - | 2,800 | 7,910 | -% |
Apr 19, 2024 | CALDWELL SUTTER CAPITAL, INC. | reduced | -50.00 | -397 | 972 | -% |
Apr 15, 2024 | Medicxi Ventures Management (Jersey) Ltd | unchanged | - | 66,676,900 | 225,584,000 | 50.22% |
Apr 12, 2024 | Vida Ventures Advisors, LLC | unchanged | - | 13,132,300 | 44,429,500 | 24.68% |
Unveiling Centessa Pharmaceuticals Limited's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Date Filed | Form Type | Document | |
---|---|---|---|
Peers (Alternatives to Centessa Pharmaceuticals Limited)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 48.1B | 6.8B | -8.06 | 7.03 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.0B | 2.0B | -57.25 | 9.49 | ||||
BMRN | 15.9B | 2.5B | 77.41 | 6.43 | ||||
INCY | 11.9B | 3.8B | 15.99 | 3.16 | ||||
MID-CAP | ||||||||
APLS | 5.7B | 396.6M | -10.83 | 14.44 | ||||
BBIO | 5.2B | 107.9M | -9.5 | 48.09 | ||||
AXSM | 3.5B | 270.6M | -14.69 | 12.99 | ||||
ARWR | 3.0B | 240.7M | -10.07 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.92 | 3.87 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.79 | 4.45 | ||||
NVAX | 659.2M | 983.7M | -1.21 | 0.67 | ||||
CRBP | 400.8M | 881.7K | -8.99 | 466.16 | ||||
INO | 280.7M | 4.9M | -2.08 | 57.68 | ||||
IBIO | 7.0M | 2.1M | -0.26 | 2.14 |
Centessa Pharmaceuticals Limited News
Income Statement (Quarterly) | |||
Description | (%) Q/Q | 2023Q4 | 2022Q4 |
S&GA Expenses | -10.6% | 12,315,000 | 13,768,000 |
EBITDA Margin | -Infinity% | -24.14 | - |
Interest Expenses | 16.7% | 2,570,000 | 2,202,500 |
Income Taxes | 276.0% | 1,168,500 | -664,000 |
Earnings Before Taxes | 18.6% | -35,693,000 | -43,837,000 |
EBT Margin | -Infinity% | -25.70 | - |
Net Income | 14.7% | -36,837,000 | -43,173,000 |
Net Income Margin | -Infinity% | -22.05 | - |
Free Cashflow | 40.5% | -31,078,000 | -52,216,000 |
Balance Sheet | |||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -4.5% | 360 | 377 | 393 | 404 | 444 | 479 | 521 | 582 | 630 | 612 | 644 | - |
Current Assets | -5.2% | 315 | 332 | 350 | 384 | 438 | 477 | 519 | 581 | 629 | 612 | 644 | 11.00 |
Cash Equivalents | -25.3% | 128 | 171 | 145 | 260 | 394 | 445 | 484 | 544 | 595 | 579 | 614 | 7.00 |
Net PPE | -5.7% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
Liabilities | 5.1% | 124 | 118 | 116 | 111 | 108 | 106 | 101 | 102 | 138 | 63.00 | 58.00 | 9.00 |
Current Liabilities | 12.7% | 39.00 | 35.00 | 34.00 | 30.00 | 38.00 | 38.00 | 34.00 | 27.00 | 25.00 | 29.00 | 24.00 | 9.00 |
Long Term Debt | 2.3% | 76.00 | 74.00 | 73.00 | 72.00 | 70.00 | 68.00 | 67.00 | 75.00 | 76.00 | - | - | - |
LT Debt, Non Current | 2.3% | 76.00 | 74.00 | 73.00 | 72.00 | 70.00 | 68.00 | 67.00 | 75.00 | 76.00 | - | - | - |
Shareholder's Equity | -8.9% | 236 | 259 | 277 | 293 | 336 | 373 | 420 | 480 | 492 | 549 | 586 | - |
Retained Earnings | -5.1% | -752 | -716 | -677 | -652 | -601 | -558 | -504 | -440 | -385 | -324 | -284 | -9.22 |
Additional Paid-In Capital | 1.3% | 987 | 974 | 953 | 946 | 939 | 933 | 926 | 920 | 876 | 871 | 867 | - |
Shares Outstanding | 1.2% | 99.00 | 98.00 | 95.00 | 95.00 | 95.00 | 94.00 | 92.00 | 91.00 | 90.00 | 70.00 | 64.00 | - |
Float | - | - | - | 311 | - | - | - | 241 | - | - | - | 1,073 | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
Cashflow From Operations | 17.0% | -31,050 | -37,392 | -44,062 | -47,838 | -51,564 | -39,088 | -59,877 | -50,017 | -56,427 | -33,170 | -33,877 | -11,635 | - | -3,281 | -1,895 | - | - |
Share Based Compensation | -1.7% | 7,430 | 7,559 | 7,213 | 7,190 | 6,617 | 7,027 | 5,603 | 5,718 | 4,758 | 4,133 | 3,229 | 2,731 | - | 91.00 | 92.00 | - | - |
Cashflow From Investing | -137.5% | -18,275 | 48,706 | -71,099 | -86,336 | -446 | -16.00 | -229 | -240 | -64.00 | -48.00 | -149 | 63,517 | - | - | - | - | - |
Cashflow From Financing | -56.9% | 6,361 | 14,744 | 12.00 | - | 89.00 | 224 | 70.00 | 74.00 | 74,429 | -1,992 | 345,821 | 241,889 | - | 1,285 | 77.00 | - | - |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | 12.00 | - | - | - | - | - |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||
License and other revenue | $ 6,853 | $ 0 |
Operating expenses: | ||
Research and development | 124,405 | 155,083 |
General and administrative | 53,731 | 55,200 |
Change in fair value of contingent value rights | 0 | 1,980 |
Loss from operations | (171,283) | (212,263) |
Interest income | 10,476 | 244 |
Interest expense | (9,906) | (7,277) |
Other (expense) income, net | (5,428) | 2,342 |
Loss before income taxes | (176,141) | (216,954) |
Income tax benefit | (25,056) | (747) |
Net loss | (151,085) | (216,207) |
Other comprehensive income (loss): | ||
Foreign currency translation adjustments | 1,700 | (2,185) |
Unrealized gain on available for sale securities, net of taxes of $0.4 million | 1,290 | 0 |
Total comprehensive loss | $ (148,095) | $ (218,392) |
Net loss per ordinary share - basic (in dollars per share) | $ (1.57) | $ (2.31) |
Net loss per ordinary share - diluted (in dollars per share) | $ (1.57) | $ (2.31) |
Weighted average ordinary shares outstanding - basic (in shares) | 96,177,578 | 93,400,513 |
Weighted average ordinary shares outstanding - diluted (in shares) | 96,177,578 | 93,400,513 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 128,030 | $ 393,644 |
Short-term investments | 128,519 | 0 |
Tax incentive receivable | 37,818 | 24,166 |
Prepaid expenses and other current assets | 20,725 | 19,937 |
Total current assets | 315,092 | 437,747 |
Property and equipment, net | 1,039 | 1,168 |
Operating lease right-of-use assets | 11,914 | 0 |
Deferred tax asset | 29,647 | 3,512 |
Other non-current assets | 2,554 | 1,880 |
Total assets | 360,246 | 444,307 |
Current liabilities: | ||
Accounts payable | 11,815 | 13,836 |
Accrued expenses and other current liabilities | 27,570 | 24,502 |
Total current liabilities | 39,385 | 38,338 |
Long term debt | 75,700 | 69,800 |
Operating lease liabilities | 8,888 | 0 |
Other noncurrent liabilities | 29 | 0 |
Total liabilities | 124,002 | 108,138 |
Commitments and contingencies (Note 7) | ||
Shareholders’ equity | ||
Ordinary shares: £0.002 nominal value: 152,500,000 shares authorized; 98,774,827 shares issued and outstanding at December 31, 2023; 94,843,391 shares issued and outstanding at December 31, 2022 | 273 | 265 |
Additional paid-in capital | 987,423 | 939,261 |
Accumulated other comprehensive income (loss) | 1,493 | (1,497) |
Accumulated deficit | (752,945) | (601,860) |
Total shareholders’ equity | 236,244 | 336,169 |
Total liabilities and shareholders’ equity | $ 360,246 | $ 444,307 |